Net Loss per Share (Tables)

3 Months Ended

Mar. 31, 2017

Net Loss per Share

Schedule of basic and diluted net loss per share

	Three Months Ended March 31,
	2017			2016
Numerator:
Net loss	$	(18,753	)	$	(2,986	)
Net loss attributable to non-controlling interests	—			35
Accretion of beneficial conversion feature on Series A preferred shares	(4,000		)	—
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(22,753	)	$	(2,951	)
Denominator:
Weighted average common shares outstanding—basic and diluted	13,088,861			11,776,429
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(1.74	)	$	(0.25	)

Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share

	Three Months Ended March 31,
	2017	2016
Options to purchase common shares	4,345,344	3,247,500
Warrants to purchase common shares	815,000	275,000
	5,160,344	3,522,500